½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1445478

ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ : ¼¼°è ½ÃÀå Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ ¹× Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)

Global Endoscopic Ultrasound Needles - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Mordor Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼¼°è ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 1¾ï 5,206¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2029³â¿¡´Â 2¾ï 923¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£(2024-2029³â) µ¿¾È 6.59%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ - ½ÃÀå

COVID-19 °¨¿°º´ÀÇ ´ëÀ¯ÇàÀº ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ°í, ´ëÀ¯Çà Ãʱ⿡ ½ÃÀåÀº ¸·´ëÇÑ ¼Õ½Ç¿¡ Á÷¸éÇß½À´Ï´Ù. Àå±â°£ÀÇ ºÀ¼â¿Í ¹ÙÀÌ·¯½º È®»ê ¾ïÁ¦¸¦ À§ÇÑ ±ÔÁ¦°¡ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇß½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 1¿ù Journal of Clinical Pathology¿¡ °ÔÀçµÈ ±â»ç¿¡ µû¸£¸é, ºÏ¾ÆÀÏ·£µåÀÇ COVID-19 °¨¿°º´ À¯ÇàÀº ¼Ò±Ô¸ð »ý°Ë ½Ã¼ú Á¦°ø¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ´Ù°í ÇÕ´Ï´Ù. ±×·¯³ª ÇöÀç Àü¿°º´ÀÌ ÁøÁ¤µÇ°í Àֱ⠶§¹®¿¡ Á¤»óÀûÀÎ »ý°Ë ÀýÂ÷´Â Á¤»óÀûÀ¸·Î ¼öÇàµÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ Á¶»ç ´ë»ó ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ¾ÈÁ¤ÀûÀÎ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħÀº Ä¡·á ¸ñÀû°ú Áø´Ü ¸ñÀû ¸ðµÎ¿¡ »ç¿ëµË´Ï´Ù. ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå µ¿·ÂÀº ³ëÀÎ Àα¸ÀÇ Áõ°¡¿Í ¼ÒÈ­±â¾Ï ¹ßº´·üÀÇ Áõ°¡ÀÔ´Ï´Ù. ÃéÀå¾Ï, °£¾Ï, °£ ´ãµµ¾Ï, Æó¾Ï, À§Àå¾Ï°ú °°Àº ¸¸¼º ÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ȯÀÚµéÀº ÃÖ¼Ò Ä§½ÀÀû ¼ö¼úÀ» ¼±È£ÇÏ°í ÀÖ½À´Ï´Ù. ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ°ú °ü·ÃµÈ ±â¼ú ¹ßÀüÀÇ Áõ°¡´Â ÇâÈÄ ¸î ³â µ¿¾È ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.

PubMed°¡ 2021³â 6¿ù¿¡ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é, 18°³¿ù µ¿¾È 800¸íÀÇ È¯ÀÚ¸¦ ¹«ÀÛÀ§·Î ¹èÁ¤ÇÏ°í 771¸íÀ» ºÐ¼®ÇÏ¿© ³»½Ã°æ ÃÊÀ½ÆÄ À¯µµÇÏ ¼¼Ä§ »ý°Ë(EUS-FNB)ÀÇ Áø´Ü Á¤È®µµ¿¡ ´ëÇÑ ½Å¼ÓÇÑ ÇöÀå Æò°¡(ROSE)ÀÇ ÀÌÁ¡À» È®ÀÎÇß½À´Ï´Ù. 385°ÇÀÇ ½Å¼ÓÇÑ ÇöÀå Æò°¡(ROSE) ºÐ¼®¿¡¼­ 96.4%ÀÇ Á¤È®µµ¸¦ º¸¿´½À´Ï´Ù. ROSE°¡ ¾ø´Â ³ª¸ÓÁö 386¸íÀº 97.4%, Àý´ë À§Çèµµ Â÷ÀÌ´Â 1.0%¿´½À´Ï´Ù. ÀÌ ¿¬±¸´Â ³»½Ã°æ ÃÊÀ½ÆÄ À¯µµÇÏ ¹Ì¼¼Ä§ »ý°Ë(EUS-FNB)ÀÌ Ã游¼º ÃéÀå º´º¯(SPL)¿¡¼­ ³ôÀº Á¤È®µµ¸¦ º¸¿´´Ù°í °á·ÐÁö¾ú½À´Ï´Ù. °íÇü ÃéÀå º´º¯¿¡´Â ÁÖ·Î ¼±¾Ï, ½Å°æ³»ºÐºñ Á¾¾ç, °íÇü ¼ººÐÀ» Æ÷ÇÔÇÑ ³¶¼º ÃéÀå ½Å»ý¹°, °íÇü °¡¼ºÀ¯µÎ»ó Á¾¾ç, ÃéÀå¾Æ¼¼Æ÷Á¾, ÃéÀ帲ÇÁÁ¾, ÃéÀå ÀüÀÌ µîÀÌ Æ÷ÇԵ˴ϴÙ. µû¶ó¼­ ¾Ï ºÐ¾ßÀÇ »õ·Î¿î ¿¬±¸ °³¹ß·Î À̾îÁö´Â ÁøÇà ÁßÀÎ Á¶»ç ¹× ¿¬±¸´Â ÁÖ¿ä ½ÃÀå Âü¿©Àڵ鿡°Ô Á¶»ç ´ë»ó ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ ¼ö ÀÖ´Â Àü·«Àû Á¶Ä¡¸¦ ÃëÇϵµ·Ï Ã˱¸ÇÏ°í ÀÖ½À´Ï´Ù.

¾Ï À¯º´·üÀÇ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ICMR ±¹¸³Áúº´Á¤º¸¿¬±¸¼¾ÅÍ°¡ 2021³â ¹ßÇ¥ÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é ÀεµÀÇ 0-14¼¼ ³²³à ¼Ò¾Æ¾ÏÀÇ °ÅÀÇ Àý¹ÝÀÌ ¹éÇ÷º´À̾ú½À´Ï´Ù. 2021³â À¯º´·üÀº ³²ÀÚ¾ÆÀÌ 46.4%, ¿©ÀÚ¾ÆÀÌ 44.3%¿´½À´Ï´Ù. ³²ÀÚ¾ÆÀÌ¿¡°Ô ÈçÇÑ ¶Ç ´Ù¸¥ ¼Ò¾Æ¾ÏÀº ¸²ÇÁÁ¾(16.4%), ¿©ÀÚ¾ÆÀÌ¿¡°Ô ÈçÇÑ ¼Ò¾Æ¾ÏÀº ¾Ç¼º°ñÁ¾¾ç(8.9%)À¸·Î ³ªÅ¸³µ½À´Ï´Ù.

¶ÇÇÑ, ÀÌ Áö¿ª ½ÃÀå ±â¾÷µéÀÇ Á¦Ç° Ãâ½Ã°¡ Áõ°¡Çϸ鼭 ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, Micro-Tech Endoscopy´Â 2021³â 10¿ù¿¡ ÀÚ»çÀÇ ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħÀÎ Areus FNA Needle°ú Trident FNB NeedleÀÇ Çâ»óµÈ ¹öÀüÀ» Ãâ½ÃÇß½À´Ï´Ù.

µû¶ó¼­ ¾Ï À¯º´·ü Áõ°¡, ¾Ï Áø´Ü ¹× Ä¡·á¿¡ ´ëÇÑ ¿¬±¸ ¿¬±¸ Áõ°¡, ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¦Ç° Ãâ½Ã Áõ°¡¿Í °°Àº ¾Õ¼­ ¾ð±Þ ÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¬±¸ ´ë»ó ½ÃÀåÀº ¿¬±¸ ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ Á¶ÀÛ¿¡ ´ëÇÑ Àü¹® Áö½ÄÀ» °®Ãá Àü¹®°¡°¡ ºÎÁ·ÇÏ¿© ½ÃÀå ¼ºÀåÀ» ¾ïÁ¦ÇÏ°í ÀÖ½À´Ï´Ù.

ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ ½ÃÀå µ¿Çâ

»ý°ËħÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå¿¡¼­ »ó´çÇÑ Á¡À¯À²À» À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»ó

»ý°Ëħ(EUS-FNB) ºÎ¹®Àº Á¡¸·ÇÏ º´º¯, ¸²ÇÁÁ¾, ÀÚ°¡¸é¿ª¼º ÃéÀå¿° µî ´Ù¾çÇÑ ºñÃéÀå º´º¯¿¡ ´ëÇÑ ÃÊÀ½ÆÄ ³»½Ã°æ Á¦Ç°ÀÇ »ç¿ë·®ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÇâÈÄ ¸î ³â µ¿¾È ½ÃÀåÀ» Àå¾ÇÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.

¸ðµç ¾Ï¿¡ ´ëÇÑ ¿¬±¸¿Í Á¶»ç Áß¿¡¼­µµ ÃéÀå¾Ï¿¡ ´ëÇÑ Á¶»ç´Â ÃéÀå¾Ï ¹ßº´·üÀÇ Áõ°¡·Î ÀÎÇØ ÀûÀÀÀûÀ¸·Î ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. 2022³â 1¿ù ¹Ì±¹¾ÏÇùȸÀÇ µ¥ÀÌÅÍ °ËÅä¿¡ µû¸£¸é ÃéÀå¾ÏÀÇ ¾à 25%´Â Èí¿¬À¸·Î ÀÎÇØ, 20%´Â °úüÁßÀ¸·Î ÀÎÇØ, Àüü ÃéÀå¾Ï »ç·ÊÀÇ 10%´Â À¯ÀüÀû À¯Àü ÁõÈıºÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ´ç´¢º´ ȯÀÚ´Â ÃéÀå¾Ï¿¡ °É¸®±â ½±½À´Ï´Ù. 2021³â ¹Ì±¹ÀÓ»óÁ¾¾çÇÐȸ(ASCO)ÀÇ ¶Ç ´Ù¸¥ µ¥ÀÌÅÍ¿¡ µû¸£¸é ¹Ì±¹ ¼ºÀÎ 60,430¸í(³²¼º 31,950¸í, ¿©¼º 28,480¸í)ÀÌ ÃéÀå¾Ï Áø´ÜÀ» ¹ÞÀº °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÃéÀå¾Ï ȯÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó »ý°Ë ¹Ù´Ã¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù.

2021³â 11¿ù PubMed¿¡ ¹ßÇ¥µÈ ³í¹®¿¡ µû¸£¸é, ÃÖ±Ù ÃÊÀ½ÆÄ ³»½Ã°æ(EUS) À¯µµ ¹Ì¼¼Ä§ »ý°Ë(FNB)ÀÇ ¹ßÀüÀ¸·Î Á¶Á÷ ±¸Á¶ º¸Á¸¿¡ ±â¹ÝÇÑ Áø´Ü Á¤È®µµ¸¦ Çâ»ó½Ãų ¼ö ÀÖ°Ô µÇ¾ú´Ù°í ÇÕ´Ï´Ù.

¶ÇÇÑ, ÁÖ¿ä ½ÃÀå ±â¾÷µéÀÇ Á¦Ç° Ãâ½Ãµµ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, NeoDynamics AB´Â NeoNavia FlexiPulse ÇÁ·Îºê¿¡ »ç¿ëµÇ´Â »ý°Ë ¹Ù´Ã µðÀÚÀο¡ ´ëÇÑ ¹Ì±¹ ƯÇ㸦 ÃëµæÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÇÁ·ÐÆ® ·Îµù ¿ÀÇ ÆÁ »ùÇøµ ¹Ù´ÃÀº ȯÀÚÀÇ ¿Ü»óÀ» ÃÖ¼ÒÈ­Çϸ鼭 Á¶Á÷ ¼öÀ²À» ÃÖ´ëÈ­ÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÆ½À´Ï´Ù.

µû¶ó¼­ Á¡¸·ÇÏ º´º¯, ¸²ÇÁÁ¾, ÀÚ°¡¸é¿ª¼º ÃéÀå¿°°ú °°Àº ´Ù¾çÇÑ ºñÃéÀå º´º¯¿¡ ´ëÇÑ ³»½Ã°æ ÃÊÀ½ÆÄ °Ë»ç¿¡ ´ëÇÑ Á¦Ç° »ç¿ë Áõ°¡ ¹× ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¦Ç° Ãâ½Ã¿Í °°Àº ¿äÀÎÀ¸·Î ÀÎÇØÀÌ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¬±¸ÀÇ.

ºÏ¹Ì´Â ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ ½ÃÀå¿¡¼­ Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»ó

ºÏ¹Ì ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ ½ÃÀåÀº Àü ¼¼°èÀûÀ¸·Î ºÏ¹Ì°¡ Áö¹èÀûÀÔ´Ï´Ù. À̴ ij³ª´Ù¿Í ¹Ì±¹¿¡¼­ È£Èí±â, Á¾¾çÇÐ, ¼ÒÈ­±âÇÐ ºÐ¾ß¿¡¼­ ÷´Ü Áø´Ü ±â¹ýÀÇ »ç¿ëÀÌ Áõ°¡ÇÏ°í ÀÖÀ¸¸ç, ÀÌ Áö¿ª¿¡ ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Á¸ÀçÇϱ⠶§¹®ÀÔ´Ï´Ù.

2022³â ¹Ì±¹¾ÏÇùȸ°¡ ¹ßÇ¥ÇÑ ÀÚ·á¿¡ µû¸£¸é, 2022³â¿¡´Â ¹Ì±¹¿¡¼­ ¾à 343,040¸íÀÇ ¼ÒÈ­±â¾Ï ȯÀÚ°¡ »õ·Î ¹ß»ýÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¶ÇÇÑ »ý½Ä±â¾ÏÀÇ ½Å±Ô ȯÀÚ ¼ö´Â 395,600¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÀÌ·¯ÇÑ ³ôÀº ¹ßº´·ü·Î ÀÎÇØ ÀÌ·¯ÇÑ Áúº´À» Áø´ÜÇÏ°í Ä¡·áÇÏ´Â ÀýÂ÷¿¡ ´ëÇÑ ¼ö¿ä°¡ ¹ß»ýÇÕ´Ï´Ù. µû¶ó¼­ ÀÌ´Â ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ ½ÃÀåÀÇ ¼ºÀå¿¡ µµ¿òÀÌ µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ij³ª´Ù, ¹Ì±¹ µî ºÏ¹Ì ±¹°¡¿¡¼­´Â È£Èí±â, Á¾¾çÇÐ, ¼ÒÈ­±âÇÐ ºÐ¾ß¿¡¼­ ÷´Ü Áø´Ü ¹æ¹ýÀÇ »ç¿ëÀÌ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ 2022³â 11¿ù ij³ª´Ù ¾ÏÇùȸ ÀÚ·á¿¡ µû¸£¸é 2022³â¿¡´Â 233,900¸íÀÌ ¾Ï Áø´ÜÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ·¯ÇÑ ¹ßº´·ü Áõ°¡´Â ÁַΠij³ª´ÙÀÇ Àα¸ Áõ°¡¿Í °í·ÉÈ­¿¡ µû¸¥ °ÍÀ¸·Î ¾Ï ¿¹¹æÀÇ Á߿伺À» °­Á¶ÇÏ°í ÀÖ½À´Ï´Ù.

ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ ½ÃÀå¿¡¼­ ´ëºÎºÐÀÇ ¼¼°è ±â¾÷ÀÇ Á¸Àç´Â ¶ÇÇÑ ¸¹Àº Á¦Ç°¿¡ ´ëÇÑ Á¢±Ù¼ºÀ¸·Î ÀÎÇØ ÀÌ Áö¿ªÀÇ Á¶»ç ´ë»ó ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ½ÄÇ°ÀǾ౹(FDA)ÀÌ Á¦°øÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é, 2021³â 5¿ù Cook Ireland Ltd´Â ¹Ì±¹ FDA·ÎºÎÅÍ EchoTip ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ, EchoTip ProCore HD ÃÊÀ½ÆÄ »ý°Ëħ¿¡ ´ëÇÑ ÆǸŠ½ÂÀÎÀ» ¹Þ¾Ò´Ù°í ÇÕ´Ï´Ù.

¾Ï À¯º´·ü Áõ°¡, Á¦Ç° Ãâ½Ã Áõ°¡ µî À§ÀÇ ¿äÀεéÀº ºÏ¹Ì ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ ½ÃÀåÀÇ ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ »ê¾÷ °³¿ä

ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ ½ÃÀåÀº º»ÁúÀûÀ¸·Î Àû´çÈ÷ ÅëÇյǾî ÀÖ½À´Ï´Ù. ¼¼°è ÁÖ¿ä ±â¾÷µéÀº ³»½Ã°æ ÃÊÀ½ÆÄ ¹Ù´ÃÀÇ ´ëºÎºÐÀ» »ý»êÇÏ°í ÀÖ½À´Ï´Ù. ´õ ¸¹Àº ¿¬±¸ Àڱݰú ´õ ³ªÀº À¯Åë ½Ã½ºÅÛÀ» °®Ãá ½ÃÀå ¸®´õ´Â È®°íÇÑ ÀÔÁö¸¦ ±¸ÃàÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿©·¯ ¼Ò±Ô¸ð Ç÷¹À̾ µîÀåÇÏ¿© ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. ½ÃÀå ÁÖ¿ä ±â¾÷À¸·Î´Â ACE Medical Devices Pvt. Ltd, Boston Scientific Corporation, CONMED Corporation, Cook Group Incorporated, ENDO-FLEX GmbH, Medi-Globe Corporation, Medtronic PLC, Micro- Tech Endoscopy ¹× Olympus Medical Devices Pvt. Tech Endoscopy, Olympus Corporation µîÀÌ ÀÖ½À´Ï´Ù.

±âŸ ÇýÅÃ

  • ¿¢¼¿ Çü½ÄÀÇ ½ÃÀå ¿¹Ãø(ME) ½ÃÆ®
  • 3°³¿ù°£ ¾Ö³Î¸®½ºÆ® Áö¿ø

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»ç °¡Á¤°ú ½ÃÀå Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå °³¿ä
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • °í·ÉÀÚ Àα¸ Áõ°¡
    • ¼ÒÈ­°ü °ü·Ã ¾ÏÀÇ ³ôÀº ÀÌȯÀ²
    • ÃÖ¼Òħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÃÊÀ½ÆÄ ³»½Ã°æ õÀÚħ Ãë±Þ¿¡ °üÇÑ Àü¹® Áö½ÄÀÇ °á¿©
  • Porter Five Forces
    • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ´ëü Á¦Ç°ÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °­µµ

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­

  • Á¦Ç°º°
    • ÈíÀÎħ
    • »ý°Ëħ
  • ¿ëµµº°
    • ±â°üÁö EUS ħ
    • °æÀå EUS ħ
  • ÃÖÁ¾»ç¿ëÀÚº°
    • º´¿ø
    • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
    • ±âŸ ÃÖÁ¾»ç¿ëÀÚ
  • Áö¿ª
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
    • À¯·´
      • ¿µ±¹
      • ÇÁ¶û½º
      • µ¶ÀÏ
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Àεµ
      • Áß±¹
      • ÀϺ»
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¹Ì
      • ºê¶óÁú
      • ¾Æ¸£ÇîƼ³ª
      • ±âŸ ³²¹Ì

Á¦6Àå °æÀï »óȲ

  • ±â¾÷ °³¿ä
    • ACE Medical Devices Pvt. Ltd
    • Boston Scientific Corporation
    • CONMED Corporation
    • Cook Group Incorporated
    • ENDO-FLEX GmbH
    • Medi-Globe Corporation
    • Medtronic PLC
    • Micro-Tech Endoscopy
    • Olympus Corporation

Á¦7Àå ½ÃÀå ±âȸ¿Í ÇâÈÄ µ¿Çâ

ksm 24.03.18

The Global Endoscopic Ultrasound Needles Market size is estimated at USD 152.06 million in 2024, and is expected to reach USD 209.23 million by 2029, growing at a CAGR of 6.59% during the forecast period (2024-2029).

Global Endoscopic Ultrasound Needles - Market

The COVID-19 pandemic impacted the market significantly, and the market faced considerable losses during the early pandemic. Long lockdown restrictions and restrictions to control the spread of the virus hampered the market's growth. For instance, according to an article published by the Journal of Clinical Pathology in January 2021, there has been a significant impact on the provision of small biopsy procedures due to the COVID-19 pandemic in Northern Ireland. However, as the pandemic has subsided currently, normal biopsy procedures are being carried out as usual; hence the studied market is expected to have stable growth during the forecast period of the study.

Endoscopic ultrasound needles are used for both therapeutic and diagnostic purposes. The major growth driver in the endoscopic ultrasound needles market is the increasing geriatric population and the growing prevalence of gastrointestinal cancers. There has been a rising prevalence of chronic diseases, like pancreatic, liver, hepatobiliary, lung, and gastrointestinal cancers, with patients increasingly preferring minimally invasive surgical procedures. Growing technological advancements related to endoscopic ultrasound needles are likely to fuel the expansion of the endoscopic ultrasound needles market in the coming years.

According to an article published by PubMed in June 2021, when 800 patients were randomized for 18 months, 771 were analyzed to check the benefit of rapid on-site evaluation (ROSE) on the diagnostic accuracy of endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB). Among the 385 with rapid on-site evaluation (ROSE) analysis, a 96.4% accuracy result was obtained. The remaining 386 without ROSE was 97.4%, with an absolute risk difference of 1.0%. The study concluded that endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) demonstrated high accuracy in solid pancreatic lesions (SPLs). Solid Pancreatic Lesions primarily include adenocarcinoma, neuroendocrine tumors, cystic pancreatic neoplasms with solid components, solid pseudopapillary tumor, pancreatoblastoma, pancreatic lymphoma, and pancreatic metastasis. Hence, ongoing research and studies leading to new research and developments in the cancer segment inspire key market players to take strategic steps that can propel the growth of the studied market.

The rising prevalence of cancer is a major factor driving the growth of the market. For instance, according to the data published by ICMR-National Centre for Disease Informatics and Research in 2021, Leukemia accounted for nearly half of all childhood cancers in both genders in the 0-14 years age group in India; it had a prevalence of 46.4% in boys and 44.3% in girls in 2021. The other common childhood cancer in boys was found to be lymphoma (16.4%), while in girls, it was a malignant bone tumor (8.9%).

Furthermore, increasing product launches by market players in the region are also expected to enhance market growth. For instance, in October 2021, Micro-Tech Endoscopy launched an enhanced version of the company's endoscopic ultrasound needles named Areus FNA Needle and Trident FNB Needle.

Thus, due to the aforementioned factors, such as the rising prevalence of cancer, growing research studies for cancer diagnosis and treatment, and increasing product launches by key market players, the studied market is expected to experience growth during the forecast period of the study. However, the lack of professionals with expertise in operating with endoscopic ultrasound needles is restraining the market's growth.

Endoscopic Ultrasound Needles Market Trends

Biopsy Needles Expected to Hold a Significant Share in the Market Over the Forecast Period

The biopsy needles (EUS-FNB) segment is likely to dominate the market in the upcoming years due to increased product usage for the endoscopic ultrasound of different non-pancreatic lesions, such as submucosal lesions, lymphoma, autoimmune pancreatitis, etc.

Among all the cancer studies and research, pancreatic cancer research has been adaptive due to the increasing incidence of pancreatic cancer cases. As per the American Cancer Society's data review in January 2022, nearly 25% of pancreatic cancers are estimated to be caused by cigarette smoking, 20% due to overweight, and inherited genetic syndromes contributing to 10% of the total pancreatic cancer cases, where people with diabetes are more prone to have pancreatic cancer. Another data from the American Society of Clinical Oncology (ASCO) in 2021 estimated that 60,430 adults (31,950 men and 28,480 women) in the United States were diagnosed with pancreatic cancer. The growing number of cases of pancreatic cancers has been increasing the demand for biopsy needles.

As per the article published by PubMed in November 2021, the recent developments in Endoscopic Ultrasound (EUS)-Guided fine-needle biopsy (FNB) allow to associate with improved diagnostic accuracy based on preserving the tissue architecture, which is necessary to detect the typical histological features of Autoimmune Pancreatitis, which, if kept untreated, can become chronic and cause pancreatic cancer.

Furthermore, product launches by key market players are also enhancing segment growth. For instance, NeoDynamics AB announced that the Company had been granted a United States patent for its biopsy needle design employed in the NeoNavia FlexiPulse probe. The front-loaded, open-tip sampling needle has been designed to enable maximum tissue yield with minimal patient trauma.

Hence, due to factors such as increased product usage for the endoscopic ultrasound of different non-pancreatic lesions, such as submucosal lesions, lymphoma, autoimmune pancreatitis, and product launches by key market players, the segment is expected to experience growth during the forecast period of the study.

North America Expected to Hold a Significant Share in the Endoscopic Ultrasound Needles Market

The North American endoscopic ultrasound needles market has dominated globally. This is due to the growing use of advanced diagnostic procedures in pulmonology, oncology, and gastroenterology in Canada and the United States and the presence of major market players in the region.

According to the data published by the American Cancer Society in 2022, it is estimated that there will be around 343,040 new cases of digestive system cancer in the United States in 2022; it is also estimated that there will be 395,600 new cases of genital system cancer. The presence of such a high incidence rate creates a demand for procedures to diagnose and treat such diseases. This has thus helped the endoscopic ultrasound needles market grow. Moreover, there is a growing use of advanced diagnostic procedures in pulmonology, oncology, and gastroenterology in North American countries of Canada and the United States.

Furthermore, according to the data from the Canadian Cancer Society in November 2022, it is estimated that 233,900 people will be diagnosed with cancer in 2022, and this growth in incidence is largely due to Canada's growing and aging population and emphasizes the importance of cancer prevention.

The presence of most of the global players in the endoscopic ultrasound needles market is also contributing to the growth of the studied market in this region with access to a number of products. For instance, in May 2021, Cook Ireland Ltd received marketing authorization from the United States FDA for its EchoTip Ultra Endoscopic Ultrasound Needle, EchoTip ProCore HD Ultrasound Biopsy Needle, according to data provided by the Department of Health and Human Sciences (US FDA).

These factors mentioned above, such as the rising prevalence of cancer, and increasing product launches, are expected to influence the growth of the endoscopic ultrasound needles market in North America.

Endoscopic Ultrasound Needles Industry Overview

The endoscopic ultrasound needles market is moderately consolidated in nature. The global key players are manufacturing the majority of endoscopic ultrasound needles. Market leaders with more funds for research and a better distribution system have an established position. Moreover, Asia-Pacific is witnessing the emergence of some small players due to a rise in awareness, helping the market grow. Some of the major players in the market include ACE Medical Devices Pvt. Ltd, Boston Scientific Corporation, CONMED Corporation, Cook Group Incorporated, ENDO-FLEX GmbH, Medi-Globe Corporation, Medtronic PLC, Micro-Tech Endoscopy, and Olympus Corporation, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Geriatric Population
    • 4.2.2 High Prevalence of Gastrointestinal Tract-related Cancers
    • 4.2.3 Increasing Demand for Minimally Invasive Procedures
  • 4.3 Market Restraints
    • 4.3.1 Lack of Expertise in Handling Endoscopic Ultrasound Needles
  • 4.4 Porter Five Forces
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Aspiration Needles
    • 5.1.2 Biopsy Needles
  • 5.2 By Application
    • 5.2.1 Bronchial EUS Needles
    • 5.2.2 Enteral EUS Needles
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 United Kingdom
      • 5.4.2.2 France
      • 5.4.2.3 Germany
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 India
      • 5.4.3.2 China
      • 5.4.3.3 Japan
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 ACE Medical Devices Pvt. Ltd
    • 6.1.2 Boston Scientific Corporation
    • 6.1.3 CONMED Corporation
    • 6.1.4 Cook Group Incorporated
    • 6.1.5 ENDO-FLEX GmbH
    • 6.1.6 Medi-Globe Corporation
    • 6.1.7 Medtronic PLC
    • 6.1.8 Micro-Tech Endoscopy
    • 6.1.9 Olympus Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦